Global Muscle Relaxant Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Route of Administration (Oral and Injectable), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2029
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Muscle Relaxant Drugs Market
Market Report Description
The Global Muscle Relaxant Drugs Market size is expected to reach $4.7 billion by 2029, rising at a market growth of 4.3% CAGR during the forecast period.
Neuromuscular Blocking Agents are significantly capturing the market because of the increasing prevalence of skin diseases and damaging effects of ultraviolet radiation, the rising disposable income leading to increased expenditures on facial aesthetics therapy, and the rising use of neuromuscular blocking agents in surgical procedures. Thus, Neuromuscular Blocking Agents is expected to generate more than 37% share by 2029. More than 882 million individuals in 44 countries remain at risk for lymphatic filariasis in 2021, and preventative treatment is needed to halt the development of this parasitic ailment. 51 million individuals were sick as of 2018—a 74% decrease since the Global Programme to Eliminate Lymphatic Filariasis of the WHO began in 2000. Some of the factors impacting the market are the increase in Musculoskeletal Conditions, the increasing number of senior citizens, and adverse muscle relaxant side effects.
The most prevalent type of non-cancer pain is discomfort felt in musculoskeletal structures. According to the WHO, 1.71 billion people globally have musculoskeletal disorders, including rheumatoid arthritis, osteoarthritis, amputation, low back pain, neck discomfort, fractures, and other injuries. According to WHO, by 2030, one in six people will be 60 or elderly. There will be 1.4 billion individuals over 60, up from 1 billion in 2020. By 2050, the global population of individuals aged 60 and elderly will have doubled to 2.1 billion. In addition, the number of individuals aged 80 or older is projected to triple between 2020 and 2050, reaching 426 million. Due to the high need for demyelinating disease treatments among this population, the market has considerable growth potential.
However, patients with a history of liver disease, seizures, and other medical conditions or issues are at an increased risk for adverse effects. In addition, pregnant women who intend to become pregnant or are breastfeeding require special attention. As total body relaxants, muscle relaxants typically induce drowsiness or grogginess. As a result, it is unsafe to operate a vehicle or make vital decisions while under the influence of muscle relaxants.
Drug Type Outlook
Based on drug type, the market is segmented into skeletal, facial muscle relaxant drugs and neuromuscular blocking agents. The skeletal segment dominated the market with maximum revenue share in 2022. This is because skeletal muscle relaxants were initially approved to treat muscle spasms and back pain temporarily. Now, they are commonly used to treat chronic pain as well as a variety of other conditions. In addition, people seek medical assistance for a variety of reasons, but the most common one is pain. Thus, their use for the treatment of chronic pain and muscle spasms is expected to propel the segment's growth.
Route of Administration Outlook
On the basis of route of administration, the market is divided into oral and injectable. The injectable segment procured a substantial revenue share in the market in 2022. This is due to the fact that the most important companies in the market are working on the creation of innovative new items. Before undergoing general anesthesia, this muscle relaxant is given to the patient. Also, one of the most well-known applications of muscle relaxant injections in anti-aging medication is to reduce the appearance of wrinkles and lines on the forehead and the eyelids, which aids in the segment's growth.
Distribution Channel Outlook
By distribution channel, the market is classified into hospital pharmacy, retail pharmacy and online pharmacy. The hospital pharmacy segment witnessed the largest revenue share in the market in 2022. This is owing to the expanding awareness and an increase in clinical and hospital visits. In addition, the increasing geriatric population is a significant factor propelling the segment's expansion. This is due to the fact that the elderly are frequently hospitalized for a variety of chronic disorders for which they receive such medications. Thus, the segment is expected to propel due to the growing hospital admissions and the rising geriatric population.
|Market size value in 2022||USD 3.5 Billion|
|Market size forecast in 2029||USD 4.7 Billion|
|Historical Period||2019 to 2021|
|Forecast Period||2023 to 2029|
|Revenue Growth Rate||CAGR of 4.3% from 2023 to 2029|
|Number of Pages||194|
|Number of Table||340|
|Report coverage||Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling|
|Segments covered||Drug Type, Route of Administration, Distribution Channel, Region|
|Country scope||US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria|
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the market in 2022. The growth is attributed to increased government investment, a rise in the incidence of chronic diseases, and the region's high-quality infrastructure. Due to the increasing number of surgical procedures and high disposable income, the market is expected to grow. Also, the presence of a large elderly population in this region contributes to the high prevalence of chronic back pain and further surge the market growth in the region.
Free Valuable Insights: Global Muscle Relaxant Drugs Market size to reach USD 4.7 Billion by 2029
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amneal Pharmaceuticals, Inc., Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Mallinckrodt PLC, Teva Pharmaceuticals Industries Ltd., Eisai Co., Ltd., Endo International PLC, Vertical Pharmaceuticals, LLC, SteriMax Inc., and Metacel Pharmaceuticals, LLC.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Neuromuscular Blocking Agents
- Facial Muscle Relaxant Drugs
By Route of Administration
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- North America
- Rest of North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Amneal Pharmaceuticals, Inc.
- Ipsen Pharma Biotech SAS
- Merz Pharma GmbH & Co. KGaA
- Mallinckrodt PLC
- Teva Pharmaceuticals Industries Ltd.
- Eisai Co., Ltd.
- Endo International PLC
- Vertical Pharmaceuticals, LLC
- SteriMax Inc.
- Metacel Pharmaceuticals, LLC
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
What would be the size of this Market by 2029?
The Market size is projected to reach USD 4.7 billion by 2029.
What are the key driving factors and challenges in this Market?
The increasing number of senior citizens are driving the Market in coming years, however, Adverse muscle relaxant side effects restraints the growth of the Market.
What are the major top companies in the competitive landscape?
Amneal Pharmaceuticals, Inc., Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Mallinckrodt PLC, Teva Pharmaceuticals Industries Ltd., Eisai Co., Ltd., Endo International PLC, Vertical Pharmaceuticals, LLC, SteriMax Inc., and Metacel Pharmaceuticals, LLC.
Which segment shows a high revenue share of this Market in 2022?
The Oral market acquired the maximum revenue share in the Market by Route of Administration in 2022 thereby, achieving a market value of $2.6 billion by 2029.
Which segment shows the high growth rate of this Market over the forecast period?
The Online Pharmacies market has shown the high growth rate of 5.2% during (2023 - 2029).
Which region dominated the Market in 2022?
The North America market dominated the Market by Region in 2022 thereby, achieving a market value of $1.8 billion by 2029.